Published in J Eval Clin Pract on August 01, 2005
Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. Leuk Lymphoma (2012) 1.57
Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood (2012) 1.23
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin Cancer Res (2012) 1.20
Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant (2013) 1.13
American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract (2010) 1.00
Renal cell carcinoma induced Coombs negative autoimmune hemolytic anemia and severe thrombocytopenia responsive to nephrectomy. J Urol (2002) 0.97
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica (2012) 0.90
Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant (2013) 0.87
The role of growth factors in the activity of pharmacological differentiation agents. Cell Growth Differ (2002) 0.87
Occurrence of multiple myeloma in both donor and recipient after bone marrow transplantation. Am J Hematol (2002) 0.86
High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst (2005) 0.85
Cryptococcus albidus infection in a patient undergoing autologous progenitor cell transplant. Transplantation (2004) 0.82
Maintaining hemostasis in acquired von Willebrand syndrome: a review of intravenous immunoglobulin and the importance of rituximab dose scheduling. Transfusion (2012) 0.81
High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy. Muscle Nerve (2006) 0.80
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance. Mult Scler (2011) 0.78
Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma. Leuk Lymphoma (2013) 0.77
High-dose chemotherapy and multiple sclerosis. Curr Opin Oncol (2011) 0.75
Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma. Ann Hematol (2014) 0.75
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias. Br J Haematol (2012) 0.75
High-dose cyclophosphamide therapy without stem cell rescue for severe refractory autoimmune illnesses: comment on the article by Moore et al. Arthritis Rheum (2003) 0.75
Malignant pericardial effusion--an uncommon complication of multiple myeloma: case report. Heart Surg Forum (2005) 0.75
Granulocytic sarcoma presenting as bilateral adrenal masses. Am J Hematol (2005) 0.75